Cargando…
EGFR-TKI一线治疗EGFR基因突变的晚期非小细胞肺癌临床观察
BACKGROUND AND OBJECTIVE: It has been proven that epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) significantly benefits advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations in progression-free survival time with better tolerance. This study is undertak...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000121/ https://www.ncbi.nlm.nih.gov/pubmed/22613337 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.05.09 |